OCUL as of Oct 31 · 09:23 ET

OCULNasdaqPharmaceutical Preparations

Ocular Therapeutix, Inc · Brief

Next report

3 days

Nov 3 · before openest.Q3 FY26

Earnings

Expected move

Inputs

±4.5%implied · report alone

6.667.28

straddle ±14.6%

spot 6.97exp Nov 20ATM strike 7ATM straddle 1.20IV 90%

Oct 30 closereport share · term structure

Expected move

Inputs

Implied vs realized

8 reportsHistory

2 of 8≥ implied

avg implied: ±15.0%
avg realized: ±6.3%

Nov 14 '24±6.6%▼−6.42%×0.98

Mar 3 '25±11.0%▼−17.02%×1.54

May 5 '25±8.1%▼−12.16%×1.51

Aug 5 '25±11.6%▼−2.83%×0.24

Nov 4 '25±10.3%▼−4.47%×0.43

Feb 5 '26±50.7%▲+4.21%×0.08

Q1 FY26±8.0%▼−0.61%×0.08

Q2 FY26±13.6%▲+2.82%×0.21

quarterimplied−55%0+55%realized×

Q2 FY26±13.6%▲+2.82%×0.21

Q1 FY26±8.0%▼−0.61%×0.08

Feb '26±50.7%▲+4.21%×0.08

Nov '25±10.3%▼−4.47%×0.43

Aug '25±11.6%▼−2.83%×0.24

May '25±8.1%▼−12.16%×1.51

2 older reports

Mar '25±11.0%▼−17.02%×1.54

Nov '24±6.6%▼−6.42%×0.98

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 3 report · est.

Bull2 of 3

263managers reporting a position in the latest quarterly filings13F · Jun 30 '26

3tracked funds holding OCULN-PORT · Aug 31 '26

Bear2 of 3

25managers whose positions make up four fifths of reported value13F · Jun 30 '26

2 of 24largest reporting managers who reduced their stake in the latest quarter13F · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

OCUL report session

No linked exposure.

Latest changes

30 daysAll changes

Oct 20impliedImplied move: ±14.6% into Nov 3 earnings (Oct 20 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.